| Long-term administration of pegylated recombinant human megakaryocyte growth and development factor dramatically improved cytopenias in a patient with myelodysplastic syndrome. | |
| | |
MedLine Citation:
|
PMID: 12930386 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
To date, there are no curative therapeutic options for patients with myelodysplastic syndromes (MDS) other than allogeneic stem cell transplantation. We treated an MDS patient with 10 microg/kg pegylated recombinant human megakaryocyte growth and development factor (rHuMGDF) for more than 450 d. The patient's platelet counts increased from <10 x 10(9)/l to 50 x 10(9)/l. Interestingly, haemoglobin levels increased dramatically and reached over 13 g/dl without additional transfusion. Adverse events and neutralizing antibodies were not observed during treatment, suggesting that the long-term administration of rHuMGDF might be of clinical benefit to patients with MDS. |
| | |
Authors:
|
Masahiro Kizaki; Yoshitaka Miyakawa; Yasuo Ikeda |
Related Documents
:
|
15300276 - Pure red cell aplasia in zaria. a 10- year review. 8049856 - Fresh frozen plasma use in a tertiary referral hospital. 19925876 - Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and... 11502666 - Plastic bronchitis and the role of bronchoscopy in the acute chest syndrome of sickle c... 19457826 - Endometriosis of the posterior cul-de-sac: clinical presentation and findings at transv... 16319456 - Trends in incidence of colorectal cancer in jewish and arab populations in central israel. |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: British journal of haematology Volume: 122 ISSN: 0007-1048 ISO Abbreviation: Br. J. Haematol. Publication Date: 2003 Sep |
Date Detail:
|
Created Date: 2003-08-21 Completed Date: 2003-10-27 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0372544 Medline TA: Br J Haematol Country: England |
Other Details:
|
Languages: eng Pagination: 764-7 Citation Subset: IM |
Affiliation:
|
Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. makizaki@sc.itc.keio.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Bone Marrow Cells / pathology Female Hemoglobins / analysis Humans Myelodysplastic Syndromes / blood, pathology, therapy* Platelet Count Polyethylene Glycols / therapeutic use* Recombinant Proteins / therapeutic use* Thrombopoietin / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Hemoglobins; 0/Polyethylene Glycols; 0/Recombinant Proteins; 0/polyethylene glycol-recombinant human megakaryocyte growth and development factor; 9014-42-0/Thrombopoietin |
| Comments/Corrections | |
Comment In:
|
Br J Haematol. 2004 Jun;125(6):818-9
[PMID:
15180875
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Chromosome 11 rearrangements and specific MLL amplification revealed by spectral karyotyping in a pa...
Next Document: Cutaneous reactions in hairy cell leukaemia treated with 2-chlorodeoxyadenosine and allopurinol.